Hypersensitivity Reactions to Biologic Agents

摘要

Many BAs have become available as new therapeutic tools, including monoclonal antibody (mAb), cytokines, and fusion proteins. Since their approval, BA therapy had a positive impact on the long-term outcomes, such as disability and mortality, associated with both inflammatory chronic diseases and cancers; thus, in a short period of time, they have entered the mainstream of their treatment.1'2 There is a large amount of research and development being undertaken to create BAs for many serious diseases, such as rheumatoid arthritis, multiple sclerosis, bowel inflammatory diseases, and different types of cancers.3 These medications each have their unique profile in terms of efficacy, tolerability, and adverse effects; they are not deprived in toxicity, which can impair quality of life and may occasionally be life-threatening or, more frequently, lead to the interruption of treatment.